Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 16/20 | 0.49 |
| ▸ | PPARA | Q07869 | 13/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PPARD | Q03181 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6489234 | 0.91 | PPARG (0.44) | FFAR1PPARGPPARAUSP2SMN1; SMN2 | |
| SCHEMBL6503536 | 0.79 | MCL1 (0.46) | FFAR1PPARG | |
| SCHEMBL6489813 | 0.79 | MCL1 (0.43) | FFAR1PPARGPPARAPPARD | |
| SCHEMBL6487163 | 0.78 | MCL1 (0.42) | — | |
| SCHEMBL6491216 | 0.78 | FFAR4 (0.43) | FFAR1PPARGPPARAPPARD | |
| SCHEMBL6492692 | 0.77 | USP2 (0.45) | PPARGPPARAUSP2SMN1; SMN2KDM4E | |
| SCHEMBL6491201 | 0.76 | MCL1 (0.43) | — | |
| SCHEMBL6488639 | 0.76 | TARBP2 (0.47) | PPARGPPARAUSP2SMN1; SMN2KDM4E | |
| SCHEMBL6488044 | 0.75 | PIK3C2B (0.51) | — | |
| SCHEMBL6488276 | 0.75 | PIK3C2B (0.50) | PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | FFAR1 1226/4885PPARG 233/4885PPARA 665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.